{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T08:17:50Z","timestamp":1769933870735,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T00:00:00Z","timestamp":1410912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Algeta US\/Bayer HealthCare Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Clinical features of patients with castration-resistant prostate cancer (CRPC) are characterized by a high incidence of bone metastases, which are associated with impairment of quality of life, pain, skeletal-related events (SREs), and a negative impact on prognosis. Advances in the understanding of cancer cell-bone stroma interactions and molecular mechanisms have recently permitted the development of new agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Purpose.<\/jats:title>\n                  <jats:p>We review the merits, applications, and limitations of emerging data sets on bone-metastatic CRPC with a focus on radium-223, an \u03b1-emitting radiopharmaceutical, and its use in therapy for this disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>References for this review were identified through searches of PubMed and Medline databases, and only papers published in English were considered. Related links in the databases were reviewed, along with relevant published guidelines, recently published abstracts from major medical meetings, and transcripts from a recent round table of clinical investigators.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Prior to radium-223, available bone-targeted therapies demonstrated the ability to delay SREs and palliate bone pain in patients with metastatic CRPC but without evidence of improvement in overall survival (OS). In a randomized controlled phase III trial, radium-223 demonstrated the ability to improve OS and delay SREs in docetaxel-pretreated or docetaxel-unfit men with symptomatic bone-metastatic CRPC and was not associated with significantly more grade 3 or 4 adverse events than placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Radium-223 has a targeted effect on bone metastases in CRPC and has an important role in docetaxel-pretreated or docetaxel-unfit men with symptomatic bone-metastatic CRPC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2013-0472","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T06:42:55Z","timestamp":1411022575000},"page":"1012-1018","source":"Crossref","is-referenced-by-count":11,"title":["Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data"],"prefix":"10.1093","volume":"19","author":[{"given":"Charles J.","family":"Ryan","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Saylor","sequence":"additional","affiliation":[{"name":"Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason J.","family":"Everly","sequence":"additional","affiliation":[{"name":"Educational Concepts Group, LLC, Atlanta, Georgia, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[{"name":"Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,9,17]]},"reference":[{"key":"2021122309081084600_B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"2021122309081084600_B2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122309081084600_B3","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122309081084600_B4","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309081084600_B5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","article-title":"Prostate cancer bone metastases promote both osteolytic and osteoblastic activity","volume":"91","author":"Keller","year":"2004","journal-title":"J Cell Biochem"},{"key":"2021122309081084600_B6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122309081084600_B7","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B8","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122309081084600_B9","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2007.15.0367","article-title":"Pain predicts overall survival in men with metastatic castration-refractory prostate cancer","volume":"26","author":"Halabi","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B10","doi-asserted-by":"crossref","first-page":"CD003347","DOI":"10.1002\/14651858.CD003347","article-title":"Radioisotopes for metastatic bone pain","volume-title":"Cochrane Database Syst Rev","author":"Roqu\u00e9","year":"2003"},{"key":"2021122309081084600_B11","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122309081084600_B14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"2021122309081084600_B15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122309081084600_B16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122309081084600_B17","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","article-title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122309081084600_B18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl 6","key":"2021122309081084600_B19","doi-asserted-by":"crossref","first-page":"5a","DOI":"10.1200\/jco.2013.31.6_suppl.5","article-title":"Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122309081084600_B20","first-page":"LBA4518a","article-title":"Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"30","author":"Ryan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122309081084600_B22","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122309081084600_B23","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309081084600_B24","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 6","key":"2021122309081084600_B25","first-page":"27a","article-title":"Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"2021122309081084600_B27","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122309081084600_B28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":"Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomized phase II trial","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"issue":"suppl","key":"2021122309081084600_B29","first-page":"LBA5000a","article-title":"Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)","volume":"31","author":"James","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B30","first-page":"349","article-title":"Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma","volume":"14","author":"Buchali","year":"1988","journal-title":"Eur J Nucl Med"},{"key":"2021122309081084600_B31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"key":"2021122309081084600_B32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group","volume":"44","author":"Oosterhof","year":"2003","journal-title":"Eur Urol"},{"key":"2021122309081084600_B33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309081084600_B34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"key":"2021122309081084600_B35","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"2021122309081084600_B36","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1998.16.4.1574","article-title":"Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial","volume":"16","author":"Serafini","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B37","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"supp 5","key":"2021122309081084600_B38","doi-asserted-by":"crossref","first-page":"8a","DOI":"10.1200\/jco.2012.30.5_suppl.8","article-title":"Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases","volume":"30","author":"Parker","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309081084600_B39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"2021122309081084600_B40","doi-asserted-by":"crossref","first-page":"898PDa","DOI":"10.1016\/S0923-7534(20)33503-1","article-title":"Updated survival, quality of life (QOL), and safety data of radium-223 chloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA)","volume":"23","author":"Parker","year":"2012","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0472","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0472","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/10\/1012\/41862163\/oncolo_19_10_1012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/10\/1012\/41862163\/oncolo_19_10_1012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T01:58:23Z","timestamp":1640311103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/10\/1012\/6399582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,17]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,9,17]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0472","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,10,1]]},"published":{"date-parts":[[2014,9,17]]}}}